Lilly Preps To File A Rival To Lantus, But Safety Remains In Question
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly’s novel basal insulin peglispro demonstrated superiority to Sanofi’s Lantus in three Phase III trials on blood sugar control, but the insulin also increased triglycerides and liver enzymes in patients.
You may also be interested in...
FDA Heparin Immunogenicity Guidance Addresses ANDA Approvals, Brand Changes
Guidance formalizes five criteria FDA used in making a “sameness” determination for Momenta/Sandoz’s enoxaparin ANDA and lays out an approach to assessing the effect of post-approval NDA changes on a product’s immunogenicity without the need for clinical trials.
On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes
With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.